Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study examined molecular predictors of ritlecitinib efficacy in treating alopecia areata, highlighting the role of JAK3-dependent inflammation and follicular integrity as important factors in understanding disease mechanisms and potential therapeutic effectiveness.

This study found that kaempferol increased the proliferation potential of basal epidermal cells in three-dimensional skin models by enhancing integrin expression and altering cell morphology.

This study observed that patients receiving IL-2 immunotherapy developed a skin eruption characterized by burning and pruritus, which resolved shortly after stopping the infusion, suggesting that IL-2 mediated these effects.

In a murine model of alopecia areata, this study observed that the IL-2 fusion protein HCW9302 helped prevent disease development by expanding regulatory T cells and reducing disease-causing effector T cell infiltrates, suggesting potential for using IL-2 fusion proteins in alopecia areata treatment.

This study reports that 71% of patients treated with the gamma-secretase inhibitor PF-03084014 for desmoid tumors experienced dermatologic side effects, such as follicular lesions and pruritic eruptions, which were managed with topical or systemic treatments.

This review highlights the possible role of T regulatory cells in the immune-related mechanisms of alopecia areata but reports no new clinical findings.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

This article reviews treatment options and psychological impacts of alopecia areata and reports no new clinical findings.

Some people with primary cicatricial alopecia also have inflammatory bowel disease, suggesting a possible connection.

This review discusses various treatment options for Alopecia Areata, focusing on both medical and psychological approaches, and reports no new clinical results.

This review highlights recent advancements in understanding and treating alopecia, emphasizing genetic and immune factors involved in different forms, and discusses emerging therapies such as gene-editing and exosome-based treatments, though achieving complete hair regrowth remains a challenge.

This study found that genetic variants linked to hypothyroidism significantly increased the risk of developing alopecia areata, suggesting a causative connection between the two conditions.

This study found that blocking interleukin-3 improved lupus nephritis symptoms in MRL/Ipr mice, suggesting IL-3 may play a role in the disease's progression.

This study reviewed recent theories on alopecia areata's pathogenesis, highlighting its autoimmune nature due to immune privilege disruption in hair follicles, and noted current treatments have limited efficacy with high relapse rates, underscoring the need for further research into its mechanisms for better therapies.

This review discusses the role of regulatory T cells in skin, including their impact on hair follicle regeneration, wound healing, and immune tolerance, without presenting new clinical findings.

This review noted that alopecia areata is an autoimmune disease impacting hair follicles and offered insights into its complex pathogenesis involving immune responses, while highlighting ongoing research into new treatments such as Janus kinase inhibitors and other immunomodulatory drugs.

In this study, three patients with extensive alopecia areata showed varying degrees of hair regrowth after 20 weeks of treatment with ustekinumab, a cytokine-targeting therapy.

This review discusses the mechanisms underlying immune tolerance failure in alopecia areata and highlights potential therapeutic avenues for restoring hair growth and achieving sustained remission, but reports no new clinical results.

This review summarizes current understanding and genetic insights into androgenetic alopecia, female pattern hair loss, and alopecia areata, noting the potential future role of molecular diagnostics, but it reports no new clinical results.

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.

This review examines the role of innate lymphoid cells in allergic diseases and the influence of an allergic microenvironment on their plasticity, without reporting new clinical outcomes.

This study found that elevated STAT5 levels are linked to improved hair-inducing capabilities in human dermal papilla cells, and reducing STAT5 impairs hair follicle induction.

This study found that treating human dermal fibroblast cells with ginsenoside Rd increased the expression of mRNA associated with the dermal-epidermal junction, suggesting potential as an anti-aging cosmetic ingredient.

This study found that TGFbeta is a key pathway causing age-related loss of dermal fat's antimicrobial function, suggesting that targeting TGFBR might help restore skin defense against infections in older age.

This study found that the absence of Hes1 in hair follicles delays secondary hair germ activation and shortens the anagen phase, impacting HFSC self-renewal and long-term hair regeneration.

This review discusses the potential of combining low-dose IL-2 with islet antigens to enhance antigen-specific Treg function in type 1 diabetes, but reports no new clinical results.

Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.

This study observed that applying JAK-STAT pathway inhibitors to mouse and human skin led to rapid hair growth by inducing the anagen phase of hair follicles.

This review summarizes recent advances in Treg cell biology, focusing on Foxp3's role in immune regulation and therapeutic reprogramming for immune dysregulatory disorders, but reports no new clinical results.

This review discusses the JAK-STAT pathway and the use of FDA-approved JAK inhibitors for autoimmune and inflammatory diseases but reports no new research findings.